Inhibitors of human 12/15-lipoxygenase

US10287279B2 · kind B2 · utility

Assignees

• THE CHILDREN'S HOSPITAL CORPORATION · US
• The Regents of the University of California · US
• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Klaus van Leyen · Medford, US
• Theodore R. Holman · Santa Cruz, US
• David J. Maloney · Point of Rocks, US
• Ajit Jadhav · Chantilly, US
• Anton Simeonov · Rockville, US
• Ganesha RAI · Arlington, US

Key dates

• Filing date: Feb 19, 2016
• Grant date: May 14, 2019
• Expiry date: Feb 19, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D277/56
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.